Drug
Ivarmacitinib clinical trials
Also written SHR0302.
Keep track of what changes. Save the ivarmacitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- SHR0302
- 18
Combined with it in one product
Studies by the year they started
37 studies that test it; most in 2026 (9)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 16
Jiangsu HengRui Medicine Co., Ltd. (15) · Reistone Biopharma Company Limited (6) · Chinese SLE Treatment And Research Group (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Huijie Zhang (1) · Peking University People's Hospital (1) · Tongji Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
Often tested with
Tested in the same studies.
Prednisone (1) · Immune Checkpoint Inhibitors (1) · Camrelizumab (1) · Zeprumetostat (1)
Studies
Open first, then newest update. How each study uses ivarmacitinib is read from its arms, and is right about nine times in ten.
Testing it · 37
- Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07505186Written as Ivarmacitinib
- JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1DNot yet recruitingPhase 2Huijie ZhangNCT07845955Written as Ivarmacitinib
- Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus ErythematosusNot yet recruitingPhase 2/3Chinese SLE Treatment And Research GroupNCT07814664Written as Ivarmacitinib Sulfate Tablets
- Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World StudyNot yet recruitingNot applicablePeking University People's HospitalNCT07550452Written as Ivarmacitinib Sulfate Tablets
- Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaRecruitingPhase 2Fudan UniversityNCT06519526Written as SHR-0302
- Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingPhase 4Chinese SLE Treatment And Research GroupNCT07451665Written as Ivarmacitinib
- Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid ArthritisNot yet recruitingPhase 4Tongji HospitalNCT07452445Written as Ivarmacitinib
- A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental VitiligoRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07251595Written as SHR0302 Tablets
- A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched TransplantationNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07381114Written as Ivarmacitinib
- Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune IntoleranceNot yet recruitingPhase 2Fujian Cancer HospitalNCT07313202Written as Ivarmacitinib
- Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and AdultsNot yet recruitingNot applicableXiangya Hospital of Central South UniversityNCT07276620Written as Ivarmacitinib Sulfate Tablets
- A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar PustulosisRecruitingNot applicableXijing HospitalNCT07270003Written as Ivarmacitinib
- Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia RheumaticaNot yet recruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07266168Written as Ivarmacitinib tablet
- SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLCNot yet recruitingPhase 2Chunxia SuNCT06925048Written as PD-L1 inhibitor+SHR0302
- A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative ColitisRecruitingPhase 3Reistone Biopharma Company LimitedNCT05181137Written as SHR0302
- Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell LymphomaNot yet recruitingPhase 1Henan Cancer HospitalNCT05900089Written as SHR0302
- Ivarmacitinib for Refractory Behcet's SyndromeWithdrawnPhase 2Liu TianNCT07634848Written as Ivarmacitinib
- A Trial of SHR0302Base in Patients With VitiligoActive, not recruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT06790862Written as SHR0302Base gel
- A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetic Profile of Single and Multiple Dose Escalation Topical Dermal Administration of SHR0302 Alkali Gel in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT07098117Written as SHR0302 Base Gel
- A SHR0302 BA Study on Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06202612Written as SHR0302 quick release tablets
See all 37 studies that test ivarmacitinib →
Given in every arm · 1 — ivarmacitinib is usual care beside what is tested
As the comparator · 1 — what is tested is compared with ivarmacitinib
Codes
What other systems call ivarmacitinib · ClinicalTrials.gg INT000650
- MeSH (NLM) C000615713ivarmacitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K6K4B9Z5TVIVARMACITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q123499437ivarmacitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C186403IvarmacitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615713 | ivarmacitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K6K4B9Z5TV | IVARMACITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123499437 | ivarmacitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C186403 | Ivarmacitinib | One source FDA |
Also registered as ivarmacitinib sulfate (UNII CN7B3Z5G04).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.